No Data
shen zhen weiguang biological products (002880): The continuous enrichment of product approvals demonstrates the confidence in the employee stock ownership plan.
Event: On October 26, 2024, the company released the third-quarter report of 2024: the company's revenue for the first three quarters of 2024 was 0.854 billion yuan ( year-on-year +16.14% ), net income attributable to the parent 1.
shen zhen weiguang biological products (002880): Q3 profit growth rate bright, China National Pharmaceutical Group's acquisition is expected to further empower.
On October 25, 2024, shen zhen weiguang biological products released the third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.854 billion, up 16.14% year-on-year, and achieved a net income attributable to the parent of 1.83.
Weiguang Biotech: Report for the third quarter of 2024
Weiguang Biotech: 2024 Semi-Annual Report Summary
Weiguang Biotech: 2024 Semi-Annual Report
Shen Zhen Weiguang Biological Products (002880.SZ): Net income in the first half of the year was 0.1099 billion yuan, a year-on-year increase of 8.75%.
On August 27, Weiguang Biological Products (002880.SZ) announced its semi-annual report for 2024, with a half-year revenue of 0.523 billion yuan, a year-on-year increase of 14.38%; net income attributable to shareholders of the listed company was 0.1099 billion yuan, a year-on-year increase of 8.75%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.108 billion yuan, a year-on-year increase of 8.34%; and the basic earnings per share was 0.4844 yuan.
No Data
No Data